HANGZHOU TIGERMED CONSULTING CO., LTD. – Trademark Portfolio
Entity Type: 99
HANGZHOU TIGERMED CONSULTING CO., LTD. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 45 (Legal & Security Services) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include TIGERMED.
Room 1502-1, Dongguan Plaza,
NO. 618 Jiangnan Road, Binjiang Distric
Showing of trademarks Trademarks
Trademark Classifications
HANGZHOU TIGERMED CONSULTING CO., LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does HANGZHOU TIGERMED CONSULTING CO., LTD. have?
HANGZHOU TIGERMED CONSULTING CO., LTD. has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does HANGZHOU TIGERMED CONSULTING CO., LTD. file in?
HANGZHOU TIGERMED CONSULTING CO., LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are HANGZHOU TIGERMED CONSULTING CO., LTD.'s most well-known trademarks?
HANGZHOU TIGERMED CONSULTING CO., LTD.'s registered trademark portfolio includes well-known marks such as TIGERMED. These are among 5 currently registered trademarks in the portfolio.
What is HANGZHOU TIGERMED CONSULTING CO., LTD.'s trademark registration success rate?
HANGZHOU TIGERMED CONSULTING CO., LTD. has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.